| Title |
Use of Cannabinoids for Spasticity and Pain Management in MS
|
|---|---|
| Published in |
Current Treatment Options in Neurology, December 2015
|
| DOI | 10.1007/s11940-015-0385-y |
| Pubmed ID | |
| Authors |
Hardeep Chohan, Ariele L. Greenfield, Vijayshree Yadav, Jennifer Graves |
| Abstract |
Several randomized trials have demonstrated potential benefit of cannabis derivatives in the symptomatic treatment of multiple sclerosis (MS) patients. These provide class 1 and 2 evidence for cannabinoid product use for spasticity and pain in these patients. The precise best ratio or doses are not yet clear. The safety and potential long-term effects of these products on cognitive function in people with MS have not been evaluated. Since short-term memory and processing speed can be significantly impaired in many people with MS, the concern of potential cognitive impairment related to cannabis products needs consideration in clinical care and should be addressed in longer, prospective studies. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 4 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 81 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 1 | 1% |
| Unknown | 80 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 13 | 16% |
| Researcher | 12 | 15% |
| Student > Master | 8 | 10% |
| Other | 7 | 9% |
| Student > Postgraduate | 7 | 9% |
| Other | 16 | 20% |
| Unknown | 18 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 20 | 25% |
| Psychology | 13 | 16% |
| Neuroscience | 7 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 6% |
| Biochemistry, Genetics and Molecular Biology | 3 | 4% |
| Other | 13 | 16% |
| Unknown | 20 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 April 2017.
All research outputs
#13,377,574
of 22,836,570 outputs
Outputs from Current Treatment Options in Neurology
#261
of 471 outputs
Outputs of similar age
#186,766
of 391,336 outputs
Outputs of similar age from Current Treatment Options in Neurology
#2
of 3 outputs
Altmetric has tracked 22,836,570 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 471 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one is in the 44th percentile – i.e., 44% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 391,336 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one.